Diabetes mellitus
Conditions
Interventions
Combination therapy with dulaglutide and insulin group:Injection of 0.75mg dulaglutide once a week, before breakfast Multiple injection of rapid acting insulin and NPH insulin.Adjust the insulin dos
Sponsors
Kanagawa Cardiovascular and Respiratory Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1Patients treated with insulin therapy 2Patients expected to have high-dose steroid(10mg or more of prednisolone each day) during the next 6 months
Exclusion criteria
Exclusion criteria: 1Patients less than 20 years old or 80 years of age or more 2Patients who are pregnant, breastfeeding or may become pregnant 3Type 1 diabetes mellitus patients 4Insulin-dependent diabetes mellitus patients 5Patients with severe infection or severe trauma 6Patients with severe hepatic disease 7Patients with severe renal disease 8Patients with hypopituitarism and/or adrenal insufficiency 9Patients with severe gastroenteric disturbance as exemplified by severe gastro-paresis. 10Patients with a history of pancreatitis 11Patients with malnutrition 12Patients taking DPP4-I,SGLT2I,GLP1 receptor agonists except for dulaglutide 13Patients who considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HbA1c at the 24th week | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of date shown below at the 12th and 24th week. HbA1c(at the 12th week),GA,body weight,blood pressure,total cholesterol,triglyceride,LDL-cholesterol,HDL-cholesterol,fasting plasma glucose,c-peptide(at the 24th week),urine albumin(mg/gCr)(at the 24th week),KL-6 | — |
Countries
Japan
Contacts
Public ContactJunko Hamai
Kanagawa Cardiovascular and Respiratory Center Department of Endocrinology and Diabetes
Outcome results
None listed